News
NIH inventors have developed a new strategy of using Interleukin 24 (IL-24) to target the whole T-helper 17 cells (Th17) lineage and thus achieve improved efficacy in therapy of Th17-relevant autoimmune diseases such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. The Th17
The 2017 Deals of Distinction™ Award was presented to National Institutes of Health, (NIH) along with its corporate partners, AbbVie and Biogen, for a license agreement related to the development and launch of Zinbryta® for treatment of relapsing multiple sclerosis (MS) The award, one of the most
The National Institutes of Health has several grants to fight tick-borne diseases caused by flaviviruses and bacteria such as Borrelia miyamotoi. Recently, the Laboratory of Medical Zoology’s (LMZ) TickReport service at the University of Massachusetts Amherst, L2 Diagnostics of New Haven, a biotech
The NIH’s tech transfer community is pursuing new law firm contracts for managing patent prosecution matters. The current contracts end Spring of 2019. As part of the development for the new Statement of Work (SOW), the community is seeking input from outside entities on what information would be